Top

Published in:

Open Access 01-12-2018 | Review

Health-related quality of life among long-term (≥5 years) prostate cancer survivors by primary intervention: a systematic review

Published in: Health and Quality of Life Outcomes | Issue 1/2018

Abstract

Background

Due to an improving prognosis, and increased knowledge of intervention effects over time, long-term well-being among prostate cancer (PC) survivors has gained increasing attention. Yet, despite a variety of available PC interventions, experts currently disagree on optimal intervention course based on survival rates.

Methods

In January 2017, we searched multiple databases to identify relevant articles. Studies were required to assess at least two different dimensions of health-related quality of life (HRQoL) in PC survivors ≥5 years past diagnosis with validated measures.

Results

Identified studies (n = 13) were mainly observational cohort studies (n = 10), conducted in developed countries with a sample size below 100 per study arm (n = 6). External-beam radiation therapy was the most common intervention (n = 12), whereas only three studies included patients on active surveillance or on watchful waiting.

Studies were largely heterogeneous in cancer stage at diagnosis, intervention groups and instruments. All identified studies either used the EORTC QLQ-C30 (n = 5) or the SF-36 (n = 7) to assess generic HRQoL, yet 11 different instruments were employed to assess PC specific urinary, bowel and sexual symptoms. Overall, no consistent pattern between intervention and HRQoL was observed. Results from two randomized-controlled-trials (RCTs) and one observational study, comparing HRQoL by primary intervention in localized PC survivors suggest that long-term HRQoL does not differ by intervention. However, observational studies that included a combination of localized and locally advanced stage PC survivors identified HRQoL differences for various scales including physical well-being, social and role function, vitality, and role emotional.

Conclusion

This review reveals the number of publications comparing HRQoL by primary intervention in long-term PC survivors is currently limited. Robust data from two RCTs and one observational study suggest that HRQoL does not seem to differ by intervention. However, the heterogeneity of studies’ methodologies and results hindered our ability to draw a clear conclusion. Therefore, in order to answer the question of which primary intervention is superior with respect to long-term HRQoL in PC patients, more high-quality, large-scale prospective cohort studies, or RCTs with repeated HRQoL assessments, are urgently needed.

Available only for authorised users

American Cancer Society. Global Cancer Facts & Figures. Am Cancer Soc. 2015;3(Edition(700)):1–57. https://doi.org/10.1002/ijc.27711.CrossRef

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403. https://doi.org/10.1016/j.ejca.2012.12.027.CrossRefPubMed

National Cancer Institute. Cancer trends progress report. National Cancer Institute; 2012. https://progressreport.cancer.gov/after/survival#field_most_recent_estimates. Accessed 20 Feb 2017.

Sant M, Minicozzi P, Primic-Žakelj M, Otter R, Francisci S, Gatta G, Berrino F, De Angelis R. Cancer survival in Europe, 1999–2007: doing better, feeling worse? Eur J Cancer. 2015;51:2101–3.CrossRefPubMed

National Coalition of Cancer Survivorship. The NCCS Definition of a “Cancer Survivor.” http://www.canceradvocacy.org/news/defining-cancer-survivorship/. Accessed 25 June 2015.

American Cancer Society. Cancer facts and figures—2000. Atlanta: American Cancer Society; 2000.

Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932–42. https://doi.org/10.1056/NEJMoa1311593.CrossRefPubMedPubMedCentral

Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377(2):132–42. https://doi.org/10.1056/NEJMoa1615869.CrossRefPubMed

Sooriakumaran P, Nyberg T, Akre O, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502.CrossRefPubMedPubMedCentral

10.

Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71. https://doi.org/10.1016/j.eururo.2010.10.039.CrossRefPubMed

11.

Gomella LG, Johannes J, Trabulsi EJ. Current prostate cancer treatments: effect on quality of life. Urology. 2009;73(5 SUPPL):S28–35.CrossRefPubMed

12.

Ferrell BR, Grant MM, Funk B, Otis-Green S, Garcia N. Quality of life in breast cancer survivors as identified by focus groups. Psychooncology. 1997;6(1):13–23. https://doi.org/10.1002/(SICI)1099-1611(199703)6:1<13::AID-PON231>3.0.CO;2-S.CrossRefPubMed

13.

Velikova G, Stark D, Selby P. Quality of life instruments in oncology. Eur J Cancer. 1999;35(11):1571–80. https://doi.org/10.1016/S0959-8049(99)00193-8.CrossRefPubMed

14.

Iran B, Wilson PDC. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59–65.CrossRef

15.

Deimling GT, Sterns S, Bowman KF, Kahana B. The health of older-adult, long-term cancer survivors. Cancer Nurs. 2005;28(6):415–24.CrossRefPubMed

16.

Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials. JAMA. 2013;309(8):814. https://doi.org/10.1001/jama.2013.879.CrossRefPubMed

17.

Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol. 2006;18(4):775–81. https://doi.org/10.1093/annonc/mdl494.CrossRef

18.

Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24. https://doi.org/10.1056/NEJMoa1606220.CrossRefPubMed

19.

Drummond FJ, Kinnear H, Leary EO, Gavin A, Sharp L. Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. In: Results from the PiCTure (prostate cancer treatment, your experience) study; 2014. https://doi.org/10.1007/s11764-014-0419-6.CrossRef

20.

Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009;101(12):888–92. https://doi.org/10.1093/jnci/djp114.CrossRefPubMed

21.

Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. Br Med J. 2009;339:12. https://doi.org/10.1136/bmj.b4817.CrossRef

22.

Tobergte DR, Curtis S. Systematic reviews - CRD’s guidance for undertaking reviews in health care, vol. 53; 2013. https://doi.org/10.1017/CBO9781107415324.004.

23.

Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data. JAMA. 2015;313(16):1657. https://doi.org/10.1001/jama.2015.3656.CrossRefPubMed

24.

Kassianos AP, Raats MM, Gage H, Peacock M. Quality of life and dietary changes among cancer patients: a systematic review. Qual Life Res. 2014;24(3):705–19. https://doi.org/10.1007/s11136-014-0802-9.CrossRefPubMed

25.

Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed

26.

Gandek B, Sinclair SJ, Kosinski M, Ware JE. Psychometric evaluation of the SF-36 health survey in Medicare managed care. Health Care Financ Rev. 2004;25(4):5–25.PubMedPubMedCentral

27.

Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9. https://doi.org/10.1200/jco.1993.11.3.570.CrossRefPubMed

28.

Postma R. Treatment of prostate cancer. Ann Oncol. 2006;17(10):207–10. https://doi.org/10.1093/annonc/mdl261.CrossRef

29.

Prostate Cancer Foundation. What is Active Surveillance? https://www.pcf.org/c/active-surveillance/. Accessed 13 Nov 2017.

30.

Henson CC, Burden S, Davidson SE, Lal S. Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapy. In: Henson CC, editor. Cochrane database of systematic reviews. Chichester: Wiley; 2013. https://doi.org/10.1002/14651858.CD009896.pub2.CrossRef

31.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–44.CrossRefPubMed

32.

Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care. 2001;39(10):1039–47. https://doi.org/10.1097/00005650-200110000-00002.CrossRefPubMed

33.

Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Bost New Engl Med Cent. 1993:1 v. (various pagings).

34.

Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924.

35.

Berg A, Lilleby W, Bruland OB, Fossa SD. 10-year Sruvival and quality of life in PAtients with high-risk pN0 prostate cancer following definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69(4):1074–83. https://doi.org/10.1016/j.ijrobp.2007.04.031.CrossRefPubMed

36.

Brundage M, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A. Impact of radiotherapy when added to androgen deprivation therapy for locally advanced prostate cancer: long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial. J Clin Oncol. 2015;33(19):2151–7. https://doi.org/10.1200/JCO.2014.57.8724.CrossRefPubMedPubMedCentral

37.

Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–37. https://doi.org/10.1056/NEJMoa1606221.CrossRefPubMedPubMedCentral

38.

Fransson P. Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer – 15 years’ follow-up. A comparison with age-matched controls. Acta Oncol (Madr). 2008;47:852–61. https://doi.org/10.1080/02841860701654325.CrossRef

39.

Fransson P, Damber J, Widmark A. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer. Scand J Urol Nephrol ISSN. 2009;43:119–26. https://doi.org/10.1080/00365590802519396.CrossRef

40.

Galbraith ME, Arechiga A, Ramirez J, Pedro LW. Prostate cancer survivors’ and partners’ self-reports of health-related quality of life, treatment symptoms, and marital satisfaction 2.5-5.5 years after treatment | ONF. Oncol Nurs Forum. 2005;32(2):E30–41.CrossRefPubMed

41.

Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol. 2009;27(5):607–12. https://doi.org/10.1007/s00345-009-0418-9.CrossRefPubMed

42.

Johnstone PAS, Gray C, Powell CR. Quality of life in T1-3N0 prostate cancer patients treated with radiation therapy with minimum 10-year follow-up. Int J Radiat Oncol Biol Phys. 2000;46(4):833–8.CrossRefPubMed

43.

Mols F, Van De Poll-Franse LV, Vingerhoets AJJM, et al. Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study. Am Cancer Soc. 2006;107(9):2186–96. https://doi.org/10.1002/cncr.22231.CrossRef

44.

Namiki S, Tochigi T, Ishidoya S, Ito A, Numata I, Arai Y. Long-term quality of life following primary treatment in men with clinical stage T3 prostate cancer. Qual Life Res. 2011;20(1):111–8. https://doi.org/10.1007/s11136-010-9721-6.CrossRefPubMed

45.

Namiki S, Kaiho Y, Mitsuzuka K, Saito H, Yamada S, Nakagawa H. Original Article : clinical investigation long-term quality of life after radical prostatectomy : 8-year longitudinal study in Japan. Int J Urol. 2014;21:1220–6. https://doi.org/10.1111/iju.12586.CrossRefPubMed

46.

Shinohara N, Maruyama S, Shimizu S, et al. Longitudinal comparison of quality of life after real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer. J Radiat Res. 2013;54(6):1095–101. https://doi.org/10.1093/jrr/rrt049.CrossRefPubMedPubMedCentral

47.

Thong MSY, Mols F, Kil PJM, Korfage IJ, Van De Poll-franse LV. Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden. BJU Int. 2009;105:652–8. https://doi.org/10.1111/j.1464-410X.2009.08815.x.CrossRefPubMed

48.

Klein, Eric A, Vogelzang, Nicholas, Lee, Robert W, Richie, Jerome P, Ross, MER. Patient education: Prostate cancer treatment; stage I to III cancer. 2017. https://www.uptodate.com/contents/prostate-cancer-treatment-stage-i-to-iii-cancer-beyond-the-basics. Accessed 12 Oct 2017.

49.

American Cancer Society. Prostate Cancer Stages. 2016. https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/staging.html. Accessed 12 Oct 2017.

50.

Ferrell BR, Hassey Dow K, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995;4(6):523–31. https://doi.org/10.1007/BF00634747.CrossRefPubMed

51.

Ware JE, Kosisnki M, Keller SD. SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales. Boston: The Health Institute, New England Medical Center, Second Edition; 1995.

52.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76.

53.

Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA prostate cancer index: development, reliability, and validity of a health-related quality of life measure on JSTOR. Med Care. 1998;36(7):1002–12.CrossRefPubMed

54.

van Andel G, Bottomley A, Fosså SD, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44(16):2418–24. https://doi.org/10.1016/j.ejca.2008.07.030.CrossRefPubMed

55.

Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects. Support Care Cancer. 9(3):187–98. https://doi.org/10.1007/S005200000146.

56.

Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Prostate cancer index composite (Epic) for comprehensive assessment of health-related. Urology. 2000;56(6):899–905. https://doi.org/10.1016/S0090-4295(00)00858-X.CrossRefPubMed

57.

Barry MJ, Fowler FJ, O’Leary MP, et al. The American urological association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–57. discussion 1564CrossRefPubMed

58.

Lenderking R, Ph D, Barber B, et al. * a brief male sexual function inventory for urology - inventory. p. 697–706.

59.

Korfage IJ, Essink-Bot ML, Madalinska JB, Kirkels WJ, Litwin MS, de Koning HJ. Measuring disease specific quality of life in localized prostate cancer: the Dutch experience. Qual Life Res. 2003;12(4):459–64.CrossRefPubMed

60.

Rosen, Wagner, Riley. A multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(97):822–30.CrossRefPubMed

61.

Donovan JL, Peters TJ, Abrams P, Brookes ST. De aa rosette JJ, Schäfer W. Scoring the short form ICSmaleSF questionnaire. International continence society. J Urol. 2000;164(6):1948–55.CrossRefPubMed

62.

Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23(4):322–30. https://doi.org/10.1002/nau.20041.CrossRefPubMed

63.

Moinpour CM, Hayden KA, Thompson IM, Feigl P, Metch B. Quality of life assessment in southwest oncology group trials. Oncology (Williston Park). 1990;4(5):79–84. 89; discussion 104

64.

Costantini M, Musso M, Viterbori P, et al. Detecting psychological distress in cancer patients: validity of the Italian version of the hospital anxiety and depression scale. Support Care Cancer. 1999;7(3):121–7.CrossRefPubMed

65.

Marenghi C, Bellardita L, Rancati T, et al. Active surveillance in patients with low-risk prostate cancer: PRIAS experience at the national cancer institute (Milan). Anticancer Res. 2011;31:1944–5.

66.

Whiting PF, Moore THM, Jameson CM, et al. Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review. BJU Int. 2016;118(2):193–204. https://doi.org/10.1111/bju.13499.CrossRefPubMed

67.

Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53(1):68–80. https://doi.org/10.1016/j.eururo.2007.09.002.CrossRefPubMed

68.

Scott N, Fayers P, Aaronson N, et al. EORTC QLQ-C30 Reference Values. 2008;(July):419.

69.

Walters SJ. Sample size and power estimation for studies with health related quality of life outcomes : a comparison of four methods using the. 2004;17:1-17.

Title: Health-related quality of life among long-term (≥5 years) prostate cancer survivors by primary intervention: a systematic review
Publication date: 01-12-2018
Published in: Health and Quality of Life Outcomes / Issue 1/2018
Electronic ISSN: 1477-7525
DOI: https://doi.org/10.1186/s12955-017-0836-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Health-related quality of life among long-term (≥5 years) prostate cancer survivors by primary intervention: a systematic review

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement

Factors associated with health-related quality of life in patients with functional dyspepsia

Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients

Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease

The ostomy leak impact tool: development and validation of a new patient-reported tool to measure the burden of leakage in ostomy device users

Dimensionality of the Pittsburgh Sleep Quality Index: a systematic review